Crosstalk between ROS-inflammatory gene expression axis in the progression of lung disorders

Sumel Ashique,Neeraj Mishra,Shubhrajit Mantry,Ashish Garg,Nitish Kumar,Madhu Gupta,Sanjeeb Kumar Kar,Anas Islam,Sourav Mohanto,Vetriselvan Subramaniyan
DOI: https://doi.org/10.1007/s00210-024-03392-1
2024-08-31
Naunyn-Schmiedeberg s Archives of Pharmacology
Abstract:A significant number of deaths and disabilities worldwide are brought on by inflammatory lung diseases. Many inflammatory lung disorders, including chronic respiratory emphysema, resistant asthma, resistance to steroids, and coronavirus-infected lung infections, have severe variants for which there are no viable treatments; as a result, new treatment alternatives are needed. Here, we emphasize how oxidative imbalance contributes to the emergence of provocative lung problems that are challenging to treat. Endogenic antioxidant systems are not enough to avert free radical-mediated damage due to the induced overproduction of ROS. Pro-inflammatory mediators are then produced due to intracellular signaling events, which can harm the tissue and worsen the inflammatory response. Overproduction of ROS causes oxidative stress, which causes lung damage and various disease conditions. Invasive microorganisms or hazardous substances that are inhaled repeatedly can cause an excessive amount of ROS to be produced. By starting signal transduction pathways, increased ROS generation during inflammation may cause recurrent DNA damage and apoptosis and activate proto-oncogenes. This review provides information about new targets for conducting research in related domains or target factors to prevent, control, or treat such inflammatory oxidative stress-induced inflammatory lung disorders.
pharmacology & pharmacy
What problem does this paper attempt to address?